ClinicalTrials.gg

Program

pegozafermin

Also written as “Pegozafermin” and “BIO89-100”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Hypertriglyceridemia, led by 2 companies.

Furthest: phase 3, since May 2, 20238 company-led studies, 3 open or runningNext primary completion: Mar 2, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
89bio50 open or runningphase 3since May 2, 2023Aug 4, 2019none ahead
Hoffmann-La Roche33 open or runningphase 3since Mar 13, 2024Mar 13, 2024Mar 2, 2027phase 1 · NCT07835243
  • Named in Hoffmann-La Roche’s own pipeline as RG6881 pegozafermin, phase 3, as of Oct 22, 2026 (source).

Also a collaborator on its studies: prosciento-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 4, 2019First study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to 89bio89bio · NCT04048135 · 101 enrolled · United States, Puerto Rico
  2. Aug 14, 2020Phase 2 study in Hypertriglyceridemia89bio · NCT04541186 · 86 enrolled · United States, Czechia, Hungary and more
  3. Jun 10, 2021Phase 2 study in Non-alcoholic Fatty Liver Disease89bio · NCT04929483 · 222 enrolled · United States, Puerto Rico
  4. Aug 20, 2021Phase 1 study in Non-alcoholic Fatty Liver Disease89bio · NCT05022693 · 8 enrolled · United States
  5. May 2, 2023Phase 3 study in Hypertriglyceridemia89bio · NCT05852431 · 369 enrolled · United States, Argentina, Austria and more
  6. Mar 13, 2024Hoffmann-La Roche's first study: phase 3 study in Non-alcoholic Fatty Liver DiseaseNew to Hoffmann-La RocheHoffmann-La Roche · NCT06318169 · 1,350 planned · United States, Argentina, Australia and more
  7. May 14, 2024Phase 3 study in Non-alcoholic Fatty Liver DiseaseHoffmann-La Roche · NCT06419374 · 1,800 planned · United States, Argentina, Australia and more
  8. Sep 17, 2026Phase 1 study in Healthy VolunteersHoffmann-La Roche · NCT07835243 · 105 planned

Ahead

  1. Mar 2, 2027Primary completion: phase 1 study in Healthy VolunteersHoffmann-La Roche · NCT07835243
  2. Jun 30, 2028Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseHoffmann-La Roche · NCT06419374
  3. Feb 2029Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseHoffmann-La Roche · NCT06318169

TargetBeta

“A glycopegylated form of fibroblast growth factor 21 (FGF21), with metabolic regulating, anti-diabetic, anti-lipidemic, and anti-fibrotic activities. Upon administration, pegozafermin mimics FGF21, and binds to FGF21-specific receptors, FGFR1c, FGFR2c, and FGFR3c, in the liver and adipose tissue.…”NCIt, read by Claude

Other programs on FGF21

ProgramCompanyFurthest phaseStudies
efimosfermin alfaGlaxoSmithKlinephase 310
efruxiferminNovo Nordiskphase 36
zalferminNovo Nordiskphase 210

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07835243Healthy Volunteers1Not yet recruitingHoffmann-La RocheMar 2, 2027105
NCT06419374Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3RecruitingHoffmann-La RocheJun 30, 20281,800
NCT06318169Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3RecruitingHoffmann-La RocheFeb 20291,350
NCT05852431Hypertriglyceridemia · United States, Argentina, Austria and more3Completed89bioJul 7, 2025369
NCT05022693Non-alcoholic Fatty Liver Disease · United States1Completed89bioDec 21, 20218
NCT04929483Non-alcoholic Fatty Liver Disease · United States, Puerto Rico2Completed89bioFeb 14, 2023222
NCT04541186Hypertriglyceridemia · United States, Czechia, Hungary and more2Completed89bioMay 19, 202286
NCT04048135Non-alcoholic Fatty Liver Disease · United States, Puerto Rico2Completed89bioAug 28, 2020101

How it is read

Names in the registry

  • “Pegozafermin”, 6 entries
  • “BIO89-100”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.